Research And Development Expense of COSCIENS Biopharma Inc. from 31 Dec 2015 to 31 Dec 2024

Taxonomy & unit
ifrs-full: USD
Summary
COSCIENS Biopharma Inc. quarterly and annual Research And Development Expense in USD history and change rate from 31 Dec 2015 to 31 Dec 2024.
  • COSCIENS Biopharma Inc. Research And Development Expense for the quarter ending 31 Dec 2024 was $1,391,000.
  • COSCIENS Biopharma Inc. Research And Development Expense for the twelve months ending 31 Dec 2024 was $8,304,000, a 307% increase year-over-year.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2024 was $8,304,000, a 307% increase from 2023.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2023 was $2,040,000, a 49% increase from 2022.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2022 was $1,371,000, a 79% decline from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (USD)
Research And Development Expense, YoY Annual Change (%)

COSCIENS Biopharma Inc. Quarterly Research And Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $8,304,000 $1,391,000 +$4,490,000 01 Oct 2024 31 Dec 2024 20-F 09 Apr 2025 2024 FY
Q3 2024 $3,814,000 $2,799,000 +$2,363,000 +542% 01 Jul 2024 30 Sep 2024 6-K 12 Nov 2024 2024 Q3
Q2 2024 $1,451,000 $1,530,000 +$839,000 +121% 01 Apr 2024 30 Jun 2024 6-K 13 Aug 2024 2024 Q2
Q1 2024 $612,000 $2,584,000 -$1,428,000 -36% 01 Jan 2024 31 Mar 2024 6-K 16 May 2024 2024 Q1
Q4 2023 $2,040,000 $3,099,000 +$3,611,000 +54% 01 Oct 2023 31 Dec 2023 20-F 09 Apr 2025 2024 FY
Q3 2023 $1,571,000 $436,000 -$2,857,000 -87% 01 Jul 2023 30 Sep 2023 6-K 12 Nov 2024 2024 Q3
Q2 2023 $1,286,000 $691,000 -$1,707,000 -71% 01 Apr 2023 30 Jun 2023 6-K 13 Aug 2024 2024 Q2
Q1 2023 $2,993,000 $4,012,000 +$1,622,000 +68% 01 Jan 2023 31 Mar 2023 6-K 16 May 2024 2024 Q1
Q4 2022 $1,371,000 $6,710,000 -$8,573,000 -460% 01 Oct 2022 31 Dec 2022 20-F 09 Apr 2025 2024 FY
Q3 2022 $9,944,000 $3,293,000 +$1,808,000 +122% 01 Jul 2022 30 Sep 2022 6-K 09 Nov 2023 2023 Q3
Q2 2022 $8,136,000 $2,398,000 +$630,000 +36% 01 Apr 2022 30 Jun 2022 6-K 09 Aug 2023 2023 Q2
Q1 2022 $7,506,000 $2,390,000 +$932,000 +64% 01 Jan 2022 31 Mar 2022 6-K 09 May 2023 2023 Q1
Q4 2021 $6,574,000 $1,863,000 +$1,237,000 +198% 01 Oct 2021 31 Dec 2021 20-F/A 17 Jul 2024 2023 FY
Q3 2021 $5,337,000 $1,485,000 +$1,113,000 +299% 01 Jul 2021 30 Sep 2021 6-K 03 Nov 2022 2022 Q3
Q2 2021 $4,224,000 $1,768,000 +$1,579,000 +835% 01 Apr 2021 30 Jun 2021 6-K/A 04 Aug 2022 2022 Q2
Q1 2021 $2,645,000 $1,458,000 +$1,139,000 +357% 01 Jan 2021 31 Mar 2021 6-K 11 May 2022 2022 Q1
Q4 2020 $1,506,000 $626,000 +$363,000 +138% 01 Oct 2020 31 Dec 2020 20-F/A 15 Feb 2024 2022 FY
Q3 2020 $1,143,000 $372,000 -$103,000 -22% 01 Jul 2020 30 Sep 2020 6-K 04 Nov 2021 2021 Q3
Q2 2020 $1,246,000 $189,000 -$382,000 -67% 01 Apr 2020 30 Jun 2020 6-K 05 Aug 2021 2021 Q2
Q1 2020 $1,628,000 $319,000 -$209,000 -40% 01 Jan 2020 31 Mar 2020 6-K 05 May 2021 2021 Q1
Q4 2019 $1,837,000 $263,000 01 Oct 2019 31 Dec 2019 20-F 29 Mar 2022 2021 FY
Q3 2019 $475,000 +$117,000 +33% 01 Jul 2019 30 Sep 2019 6-K 05 Nov 2020 2020 Q3
Q2 2019 $571,000 -$403,000 -41% 01 Apr 2019 30 Jun 2019 6-K 06 Aug 2020 2020 Q2
Q1 2019 $528,000 01 Jan 2019 31 Mar 2019 6-K/A 11 May 2020 2020 Q1
Q3 2018 $358,000 01 Jul 2018 30 Sep 2018 6-K 07 Nov 2019 2019 Q3
Q2 2018 $974,000 01 Apr 2018 30 Jun 2018 6-K 13 Aug 2019 2019 Q2

COSCIENS Biopharma Inc. Annual Research And Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,304,000 +$6,264,000 +307% 01 Jan 2024 31 Dec 2024 20-F 09 Apr 2025 2024 FY
2023 $2,040,000 +$669,000 +49% 01 Jan 2023 31 Dec 2023 20-F 09 Apr 2025 2024 FY
2022 $1,371,000 -$5,203,000 -79% 01 Jan 2022 31 Dec 2022 20-F 09 Apr 2025 2024 FY
2021 $6,574,000 +$5,068,000 +337% 01 Jan 2021 31 Dec 2021 20-F/A 17 Jul 2024 2023 FY
2020 $1,506,000 -$331,000 -18% 01 Jan 2020 31 Dec 2020 20-F/A 15 Feb 2024 2022 FY
2019 $1,837,000 -$1,095,000 -37% 01 Jan 2019 31 Dec 2019 20-F 29 Mar 2022 2021 FY
2018 $2,932,000 -$7,772,000 -73% 01 Jan 2018 31 Dec 2018 20-F 31 Mar 2020 2019 FY
2017 $10,704,000 -$5,791,000 -35% 01 Jan 2017 31 Dec 2017 20-F 31 Mar 2020 2019 FY
2016 $16,495,000 -$739,000 -4.3% 01 Jan 2016 31 Dec 2016 20-F 01 Apr 2019 2018 FY
2015 $17,234,000 01 Jan 2015 31 Dec 2015 20-F 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.